

REMARKS


Applicants have attached an abstract on a separate sheet of paper as required by US practice. Applicants have amended the specification for purposes of adding the priority information.

Applicant respectfully requests the entry of the above preliminary amendment.

Examiner is invited and encouraged to contact the undersigned if such contact would facilitate prosecution of this application.

Respectfully submitted,


Date: March 25, 2001


Virginia C. Bennett
Reg. No. 37,092

GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709-3398
Telephone: 919-483-1012
Facsimile: 919-483-7988

CERTIFICATE OF EXPRESS MAILING (37 CFR 1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Assistant Commissioner of Patents Washington, D.C. 20231 on March 26, 2001


Marilyn Eldridge